08:00 , Mar 27, 2006 |  BioCentury  |  Finance

BioMarin chronicles

BioMarin chronicles Weekly stock price of BioMarin (BMRN; SWX:BMRN) tracked against selected events since the start of 2004. A. 4/21/04 - BMRN says it will pay $175M for the Ascent Pediatrics business of Medicis (MRX)...
08:00 , Mar 27, 2006 |  BioCentury  |  Finance

Ebb & Flow

BioMarin (BMRN; SWX:BMRN) last week tapped the debt and equity markets to the tune of $267 million in a follow-on and senior subordinated note deal. The financings punctuate the end of BMRN's pediatric detour, and...
07:00 , Jul 11, 2005 |  BioCentury  |  Strategy

BioMarin chronicles

BioMarin chronicles On the back of positive news for its enzyme replacement therapies, BMRN has almost made a round trip since it announced last April that it would focus on pediatrics. A. 4/21/04 - BMRN...
07:00 , Jul 11, 2005 |  BioCentury  |  Strategy

Cutting its losses

It's always easier to admit mistakes when someone else has made them. BioMarin Pharmaceutical Inc. is correcting course after what it says was last year's misguided acquisition of Ascent Pediatrics from Medicis Pharmaceutical Corp. The...
08:00 , Jan 17, 2005 |  BC Week In Review  |  Company News

BioMarin, Medicis deal

The companies amended the terms of BMRN's 2004 acquisition of Ascent Pediatrics, the pediatrics business of MRX (see BioCentury, April 26, 2004). As amended, the price paid by BMRN was reduced to $159 million from...
07:00 , Sep 27, 2004 |  BioCentury  |  Finance

Ebb & Flow

BioMarin's first announcement related to Orapred, the flagship of its new pediatrics focus, wasn't a great one, as the company expects no revenue contribution from the pediatric asthma drug in the second half. Moreover, there's...
07:00 , Sep 27, 2004 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Advancis (AVNC) Pacific Growth Gregory Wade Upgrade Overweight (from equal weight) Wade believes AVNC will outperform its peers in anticipation of the start of the first...
07:00 , Sep 21, 2004 |  BC Extra  |  Financial News

BioMarin lowers guidance

BioMarin (BMRN; SWX:BMRN) said it expects that recently acquired pediatric asthma drug Orapred will have "no contribution" to revenues in the second half. As a result, the company said it now expects to post a...
07:00 , Aug 16, 2004 |  BioCentury  |  Finance

Ebb & Flow

Investors reacted badly to Monday's post-market news that Barr (BRL) will receive a license from Cephalon (CEPH) to sell generic oral transmucosal fentanyl starting Feb. 3, 2007. CEPH was off $4.86 (10%) to $43 on...
07:00 , May 24, 2004 |  BC Week In Review  |  Company News

BioMarin, Medicis deal

BMRN completed its previously announced purchase of MRX's pediatrics business, Ascent Pediatrics , for $175 million in cash and stock (see BioCentury, April 26). BioMarin Pharmaceutical Inc. (BMRN; SWX:BMRN), Novato, Calif.   Medicis Pharmaceutical Corp....